EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma

Christian Rausch iD, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, Thomas Pabst

Hematological Oncology · 2025

DOI: 10.1002/hon.70143 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, 2025. Verfasst von Christian Rausch und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, LMU University Hospital, Munich, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Ki-1 Antigen, Hodgkin Disease, Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Millenium Pharmaceuticals Inc., Takeda Pharmaceuticals International.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with Hodgkin lymphoma (HL) or peripheral T‐cell lymphoma (PTCL) who relapse after high‐dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab‐vedotin (BV) is a CD30‐targeting antibody‐drug‐conjugate (ADC) used in first‐line‐, salvage‐, and maintenance‐therapy of HL, as well as first‐line‐ and salvage‐therapy of PTCL. In phase I of this trial, we could show that BV can safely be added to BeEAM‐HDCT (bendamustine, etoposide, cytarabine and melphalan). Here, we report the randomized phase II part of the trial comparing BV‐BeEAM to BeEAM alone (ClinicalTrials.gov: NCT03187210). Primary endpoint was 1‐year disease‐free survival. Inclusion of 42 patients was planned but the study was terminated early, after a futility analysis showed lack of benefit. Twenty‐five patients (HL: 11, PTCL: 14) who were planned to undergo HDCT were included. Median age was 60 years. Patients had a median of two prior therapies, and 11 were previously exposed to BV. Patients in the standard‐arm had higher disease stage and (PTCL only) higher IPI. Duration of hospitalization, recovery of neutrophils/platelets, and infections were not significantly different between arms. No treatment related death occurred. However, two patients in the BV‐arm developed grade 3 pneumonitis. After 22 months median follow‐up, overall response‐rate, complete remission‐rate, disease‐free survival and overall survival did not differ between groups. Pre‐planned subgroup‐analyses (HL‐only, PTCL‐only, only those achieving CR) did not show benefit in any subgroup. In conclusion, adding BV to BeEAM does not improve outcomes after HDCT, and may increase pulmonary toxicity. Frequent prior exposure to BV may have limited the potential benefit of the combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsKi-1 AntigenHodgkin DiseaseLymphoma, T-Cell, PeripheralHumansBrentuximab VedotinMiddle AgedFemaleMaleAgedAdultImmunoconjugatesEtoposideCytarabine

Stichwörter der Autor:innen

autologous stem‐cell transplantationbrentuximab‐vedotinhodgkin lymphomaperipheral T‐cell lymphomaphase II study

Substanzen

Brentuximab VedotinKi-1 AntigenImmunoconjugatesEtoposideCytarabine

Autor:innen und Institutionen

  • Department of Medicine III, LMU University Hospital, Munich, Germany.
  • Department of Hematology and Central Hematological Laboratory, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.
  • Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.

ORCID-Profile: Christian Rausch

Förderung

  • Millenium Pharmaceuticals Inc.
  • Takeda Pharmaceuticals International

Zitieren

APA

Rausch, C., Bacher, U., Rabaglio, M., Vorburger, C., Klingenberg, A., Banz, Y., Daskalakis, M., & Pabst, T. (2025). Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma. Hematological Oncology. https://doi.org/10.1002/hon.70143

Vancouver

Rausch C, Bacher U, Rabaglio M, Vorburger C, Klingenberg A, Banz Y, et al. Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma. Hematological Oncology. 2025. doi:10.1002/hon.70143

BibTeX
@article{Rausch2025,
  author = {Rausch, Christian and Bacher, Ulrike and Rabaglio, Manuela and Vorburger, Corinne and Klingenberg, Anke and Banz, Yara and Daskalakis, Michael and Pabst, Thomas},
  title = {Randomized Phase II Study of Brentuximab‐Vedotin With High‐Dose Chemotherapy in CD30 Positive Lymphoma},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70143}
}
Kostenlos starten →